WallStSmart

Starbucks Corporation (SBUX)vsSanofi ADR (SNY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Sanofi ADR generates 24% more annual revenue ($46.72B vs $37.70B). SNY leads profitability with a 16.7% profit margin vs 3.6%. SBUX appears more attractively valued with a PEG of 1.53. SNY earns a higher WallStSmart Score of 49/100 (D+).

SBUX

Hold

39

out of 100

Grade: F

Growth: 4.0Profit: 5.0Value: 4.7Quality: 4.3
Piotroski: 2/9Altman Z: 1.07

SNY

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 6.0Value: 4.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SBUXSignificantly Overvalued (-1135.9%)

Margin of Safety

-1135.9%

Fair Value

$8.02

Current Price

$92.70

$84.68 premium

UndervaluedFair: $8.02Overvalued
SNYSignificantly Overvalued (-89.7%)

Margin of Safety

-89.7%

Fair Value

$24.79

Current Price

$46.03

$21.24 premium

UndervaluedFair: $24.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SBUX2 strengths · Avg: 8.5/10
Market CapQuality
$104.79B9/10

Large-cap with strong market position

Free Cash FlowQuality
$1.27B8/10

Generating 1.3B in free cash flow

SNY3 strengths · Avg: 9.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Market CapQuality
$109.03B9/10

Large-cap with strong market position

Free Cash FlowQuality
$1.59B8/10

Generating 1.6B in free cash flow

Areas to Watch

SBUX4 concerns · Avg: 3.3/10
PEG RatioValuation
1.534/10

Expensive relative to growth rate

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

SNY3 concerns · Avg: 3.0/10
EPS GrowthGrowth
2.4%4/10

2.4% earnings growth

Return on EquityProfitability
6.7%3/10

ROE of 6.7% — below average capital efficiency

PEG RatioValuation
4.322/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : SBUX

The strongest argument for SBUX centers on Market Cap, Free Cash Flow.

Bull Case : SNY

The strongest argument for SNY centers on Price/Book, Market Cap, Free Cash Flow. Profitability is solid with margins at 16.7% and operating margin at 14.3%.

Bear Case : SBUX

The primary concerns for SBUX are PEG Ratio, Return on Equity, Profit Margin. A P/E of 78.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.

Bear Case : SNY

The primary concerns for SNY are EPS Growth, Return on Equity, PEG Ratio.

Key Dynamics to Monitor

SBUX profiles as a value stock while SNY is a mature play — different risk/reward profiles.

SBUX carries more volatility with a beta of 0.93 — expect wider price swings.

SNY is growing revenue faster at 6.9% — sustainability is the question.

SNY generates stronger free cash flow (1.6B), providing more financial flexibility.

Bottom Line

SNY scores higher overall (49/100 vs 39/100), backed by strong 16.7% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Starbucks Corporation

CONSUMER CYCLICAL · RESTAURANTS · USA

Starbucks Corporation is an American multinational chain of coffeehouses and roastery reserves headquartered in Seattle, Washington. As the world's largest coffeehouse chain, Starbucks is seen to be the main representation of the United States' second wave of coffee culture.

Sanofi ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

Want to dig deeper into these stocks?